proxyvotesnow.com

Home › Companies › AKERO THERAPEUTICS INC. › 2023-2024

AKERO THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and AKERO THERAPEUTICS INC.’s Form 8-K, filed 2024-06-12 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 6Ballot items
  • 206Asset managers
  • 1,548Fund votes
  • 2024-06-07Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore AKERO THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by AKERO THERAPEUTICS INC.

These tallies are AKERO THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-12 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AKERO THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-06-07
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Seth L. Harrison, M.D. 16,924,611---- 38,742,9933,920,264 Plurality election
Elect Director: Graham Walmsley, M.D., Ph.D. 35,755,718---- 19,911,8863,920,264 Majority: yes
Elect Director: Yuan Xu, Ph.D. 18,067,658---- 37,599,9463,920,264 Plurality election
The Company's stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2. 59,238,34937,608311,911 --0 Majority: yes
The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 3. 52,835,9742,548,327283,303 --3,920,264 Majority: yes
The Company's stockholders approved an amendment to the Fourth Amended and Restated Certificate of Incorporation in Proposal 4. 51,521,7033,864,198281,703 --3,920,264 Majority: yes

Source: AKERO THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-12 — read the filing on EDGAR.

How asset managers voted at the AKERO THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 206 asset managers that disclosed a AKERO THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To consider and act upon a non- binding, advisory vote to approve the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 10 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 52,835,974AGAINST: 2,548,327

AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 3.”): 52,835,974 for, 2,548,327 against, per its Form 8-K filed 2024-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 205 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 95%
FOR: 95.2%AGAINST: 4.4%ABSTAIN: 0.4%NOT VOTED: 0.0%
Largest asset managers voting on “To consider and act upon a non- binding, advisory vote to approve the compensation of our named executive offi” at AKERO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price8,980,7130 00For
Janus Henderson6,170,6090 00For
State Street5,753,90311,145 00For
GENERAL ATLANTIC, L.P.5,233,9890 00For
Vanguard5,233,7040 00For
Wellington4,356,2600 00For
BlackRock4,292,51416,619 00For
RTW INVESTMENTS, LP3,258,6090 00For
JANUS INVESTMENT FUND2,103,3330 00For
AllianceBernstein1,966,2800 00For
Redmile Group, LLC1,858,7020 00For
Boxer Capital, LLC1,676,7330 00For
GEODE CAPITAL MANAGEMENT, LLC1,414,1360 00For
Fidelity1,395,3760 00For
Rock Springs Capital Management LP1,299,8880 00For
FRED ALGER MANAGEMENT, LLC59,7031,199,976 00Against
Yiheng Capital Management, L.P.1,145,1440 00For
ALKEON CAPITAL MANAGEMENT LLC1,072,0510 00For
Charles Schwab1,053,8690 00For
Logos Global Management LP800,0000 00For
Northern Trust545,62754 00For
JPMorgan502,0910 00For
Hartford489,2880 00For
Advantage Advisers Xanthus Fund, L.L.C.460,9360 00For
Artisan435,8590 00For

Showing the 25 largest of 205 asset managers. See all 205 in the interactive database.

2. Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Graham Walmsley, M.D., Ph.D

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

64% Majority: yes · of votes cast

FOR 64%WITHHELD 36%
FOR: 35,755,718WITHHELD: 19,911,886

AKERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Graham Walmsley, M.D., Ph.D.”): 35,755,718 for, 19,911,886 withheld, per its Form 8-K filed 2024-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 66 asset managers below cast 100% of the shares they voted on this item FOR (13,737,745 for, 0 against).

FOR 58%ABSTAIN 42%
FOR: 13,737,745 (58.4%)ABSTAIN: 9,770,727 (41.6%)
Largest asset managers voting on “Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her suc” at AKERO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,046,3250 12,4000For
T. Rowe Price00 3,875,1620Abstain
BlackRock2,380,1190 00For
State Street2,290,4220 33,6460For
JANUS INVESTMENT FUND191,8790 1,911,4540Abstain
Fidelity1,359,2560 26,6040For
AllianceBernstein00 521,1010Abstain
Charles Schwab518,5590 00For
Hartford489,2880 00For
Advantage Advisers Xanthus Fund, L.L.C.00 460,9360Abstain
ALGER INSTITUTIONAL FUNDS00 335,7290Abstain
AB DISCOVERY GROWTH FUND, INC.00 299,8670Abstain
ALGER FUNDS II00 285,4890Abstain
Principal1520 279,4020Abstain
Equitable94,7150 184,1340Abstain
ALGER FUNDS00 265,0960Abstain
Direxion Shares ETF Trust00 240,7200Abstain
FINANCIAL INVESTORS TRUST00 224,8290Abstain
JPMorgan223,0940 00For
Aberdeen00 199,2370Abstain
Artisan191,7900 00For
John Hancock98,5560 53,0430For
TIAA143,3240 00For
QUANTITATIVE MASTER SERIES LLC114,7020 00For
Northwestern Mutual96,0680 00For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

3. Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Seth L. Harrison, M.D.

DIRECTOR ELECTIONSCompany result: Plurality election

Combines 3 wordings of this item as funds reported it.

30% Plurality election · of votes cast

FOR 30%WITHHELD 70%
FOR: 16,924,611WITHHELD: 38,742,993

AKERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Seth L. Harrison, M.D.”): 16,924,611 for, 38,742,993 withheld, per its Form 8-K filed 2024-06-12 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.

The 66 asset managers below cast 100% of the shares they voted on this item FOR (3,720,180 for, 0 against).

FOR 16%ABSTAIN 84%
FOR: 3,720,180 (15.8%)ABSTAIN: 19,788,292 (84.2%)
Largest asset managers voting on “Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her suc” at AKERO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,503,2900 1,555,4350For
T. Rowe Price00 3,875,1620Abstain
BlackRock00 2,380,1190Abstain
State Street25,0110 2,299,0570Abstain
JANUS INVESTMENT FUND191,8790 1,911,4540Abstain
Fidelity00 1,385,8600Abstain
AllianceBernstein00 521,1010Abstain
Charles Schwab00 518,5590Abstain
Hartford00 489,2880Abstain
Advantage Advisers Xanthus Fund, L.L.C.00 460,9360Abstain
ALGER INSTITUTIONAL FUNDS00 335,7290Abstain
AB DISCOVERY GROWTH FUND, INC.00 299,8670Abstain
ALGER FUNDS II00 285,4890Abstain
Principal00 279,5540Abstain
Equitable00 278,8490Abstain
ALGER FUNDS00 265,0960Abstain
Direxion Shares ETF Trust00 240,7200Abstain
FINANCIAL INVESTORS TRUST00 224,8290Abstain
JPMorgan00 223,0940Abstain
Aberdeen00 199,2370Abstain
Artisan00 191,7900Abstain
John Hancock00 151,5990Abstain
TIAA00 143,3240Abstain
QUANTITATIVE MASTER SERIES LLC00 114,7020Abstain
Northwestern Mutual00 96,0680Abstain

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

4. Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Yuan Xu, Ph.D

DIRECTOR ELECTIONSCompany result: Plurality election

Combines 3 wordings of this item as funds reported it.

32% Plurality election · of votes cast

FOR 32%WITHHELD 68%
FOR: 18,067,658WITHHELD: 37,599,946

AKERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Yuan Xu, Ph.D.”): 18,067,658 for, 37,599,946 withheld, per its Form 8-K filed 2024-06-12 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.

The 66 asset managers below cast 100% of the shares they voted on this item FOR (4,251,946 for, 0 against).

FOR 18%ABSTAIN 82%
FOR: 4,251,946 (18.1%)ABSTAIN: 19,256,526 (81.9%)
Largest asset managers voting on “Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her suc” at AKERO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,503,2900 1,555,4350For
T. Rowe Price00 3,875,1620Abstain
BlackRock00 2,380,1190Abstain
State Street25,0110 2,299,0570Abstain
JANUS INVESTMENT FUND191,8790 1,911,4540Abstain
Fidelity7,2810 1,378,5790Abstain
AllianceBernstein00 521,1010Abstain
Charles Schwab00 518,5590Abstain
Hartford00 489,2880Abstain
Advantage Advisers Xanthus Fund, L.L.C.00 460,9360Abstain
ALGER INSTITUTIONAL FUNDS00 335,7290Abstain
AB DISCOVERY GROWTH FUND, INC.00 299,8670Abstain
ALGER FUNDS II00 285,4890Abstain
Principal00 279,5540Abstain
Equitable00 278,8490Abstain
ALGER FUNDS00 265,0960Abstain
Direxion Shares ETF Trust00 240,7200Abstain
FINANCIAL INVESTORS TRUST00 224,8290Abstain
JPMorgan223,0940 00For
Aberdeen00 199,2370Abstain
Artisan191,7900 00For
John Hancock00 151,5990Abstain
TIAA00 143,3240Abstain
QUANTITATIVE MASTER SERIES LLC00 114,7020Abstain
Northwestern Mutual00 96,0680Abstain

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

5. TO APPROVE AN AMENDMENT TO OUR FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, TO LIMIT THE LIABILITY OF CERTAIN OFFICERS OF AKERO THERAPEUTICS, INC., AS PERMITTED BY RECENT AMENDMENTS TO DELAWARE LAW.

SHAREHOLDER RIGHTS AND DEFENSESMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 51,521,703AGAINST: 3,864,198

AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved an amendment to the Fourth Amended and Restated Certificate of Incorporation in Proposal 4.”): 51,521,703 for, 3,864,198 against, per its Form 8-K filed 2024-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 66 asset managers below cast 99% of the shares they voted on this item FOR (23,165,468 for, 332,802 against).

FOR 99%
FOR: 23,165,468 (98.5%)AGAINST: 332,802 (1.4%)ABSTAIN: 10,202 (0.0%)
Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, TO LIMIT THE LIABILIT” at AKERO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,058,7250 00For
T. Rowe Price3,875,1620 00For
BlackRock2,380,1190 00For
State Street2,320,0953,973 00For
JANUS INVESTMENT FUND2,103,3330 00For
Fidelity1,385,8600 00For
AllianceBernstein521,1010 00For
Charles Schwab518,5590 00For
Hartford489,2880 00For
Advantage Advisers Xanthus Fund, L.L.C.460,9360 00For
ALGER INSTITUTIONAL FUNDS335,7290 00For
AB DISCOVERY GROWTH FUND, INC.299,8670 00For
ALGER FUNDS II285,4890 00For
Principal279,5540 00For
Equitable278,8490 00For
ALGER FUNDS265,0960 00For
Direxion Shares ETF Trust240,7200 00For
FINANCIAL INVESTORS TRUST224,8290 00For
JPMorgan0223,094 00Against
Aberdeen199,2370 00For
Artisan191,7900 00For
John Hancock151,5990 00For
TIAA143,3240 00For
QUANTITATIVE MASTER SERIES LLC114,7020 00For
Northwestern Mutual96,0680 00For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

6. TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 59,238,349AGAINST: 37,608

AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2.”): 59,238,349 for, 37,608 against, per its Form 8-K filed 2024-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 66 asset managers below cast 100% of the shares they voted on this item FOR (23,498,270 for, 0 against).

FOR 99.9%
FOR: 23,498,270 (100.0%)ABSTAIN: 10,202 (0.0%)
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR TH” at AKERO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,058,7250 00For
T. Rowe Price3,875,1620 00For
BlackRock2,380,1190 00For
State Street2,324,0680 00For
JANUS INVESTMENT FUND2,103,3330 00For
Fidelity1,385,8600 00For
AllianceBernstein521,1010 00For
Charles Schwab518,5590 00For
Hartford489,2880 00For
Advantage Advisers Xanthus Fund, L.L.C.460,9360 00For
ALGER INSTITUTIONAL FUNDS335,7290 00For
AB DISCOVERY GROWTH FUND, INC.299,8670 00For
ALGER FUNDS II285,4890 00For
Principal279,5540 00For
Equitable278,8490 00For
ALGER FUNDS265,0960 00For
Direxion Shares ETF Trust240,7200 00For
FINANCIAL INVESTORS TRUST224,8290 00For
JPMorgan223,0940 00For
Aberdeen199,2370 00For
Artisan191,7900 00For
John Hancock151,5990 00For
TIAA143,3240 00For
QUANTITATIVE MASTER SERIES LLC114,7020 00For
Northwestern Mutual96,0680 00For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Largest AKERO THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of AKERO THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting.

Top AKERO THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#Asset manager Shares voted
1T. Rowe Price 8,980,713
2Janus Henderson 6,170,609
3State Street 5,765,048
4GENERAL ATLANTIC, L.P. 5,233,989
5Vanguard 5,233,704
6Wellington 4,356,260
7BlackRock 4,309,133
8RTW INVESTMENTS, LP 3,258,609
9JANUS INVESTMENT FUND 2,103,333
10AllianceBernstein 1,966,280

Shown as share counts, not percentages: no shares-outstanding figure has been matched to AKERO THERAPEUTICS INC. for the 2023-2024 season, so there is no denominator to divide by.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At AKERO THERAPEUTICS INC.'s shareholder meeting held 2024-06-07, in the 2023-2024 proxy season, 206 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,548 separate fund positions. On the most widely held item on that ballot — To consider and act upon a non- binding, advisory vote to approve the compensation of our named… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: AKERO THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-12.

AKERO THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.